Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.

ABSTRACT:

Objective

Dyskinesia is a known side-effect of the treatment of Parkinson's Disease (PD). We examined the influence of haplotypes in three dopamine receptors (DRD1, DRD2 and DRD3) and the Brain Derived Neurotrophic Factor (BDNF) on dyskinesia.

Methods

Patient data were drawn from a population-based case-control study. We included 418 patients with confirmed diagnoses by movement disorder specialists, using levodopa and a minimum three years disease duration at the time of assessment. Applying Haploview and Phase, we created haploblocks for DRD1-3 and BDNF. Risk scores for DRD2 and DRD3 were generated. We calculated risk ratios using Poisson regression with robust error variance.

Results

There was no difference in dyskinesia prevalence among carriers of various haploty

SUBMITTER: Kusters CDJ 

PROVIDER: S-EPMC5803389 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature